Core Insights - The "Liver Future Summit Dialogue" series, initiated in 2025, aims to enhance the diagnosis and treatment of fatty liver disease in the northwest region of China, with significant participation and collaboration among various healthcare institutions [1][3] - The initiative addresses the rising prevalence of fatty liver disease, particularly among younger populations, and aims to establish a multi-disciplinary approach to improve healthcare delivery in underserved areas [3] Group 1: Event Overview - The series has successfully conducted 9 academic exchange and free clinic events, attracting a total of 3,800 participants [1] - The events are supported by the Chinese Medical Doctor Association and involve partnerships with local hospitals to enhance healthcare capabilities through resource sharing and collaborative efforts [1][3] Group 2: Health Challenges and Solutions - Fatty liver disease has become a significant public health issue in China, particularly in the northwest, where dietary habits and healthcare resource distribution contribute to its rising incidence [3] - The initiative aims to create a "provincial-city-county" fatty liver prevention alliance, promoting a replicable chronic disease management model to improve local healthcare standards [3] Group 3: Corporate Social Responsibility - Tianshili Pharmaceutical Group emphasizes social responsibility and health care as core values, launching various health initiatives in 2025, including projects focused on stroke and cardiovascular disease prevention [4] - The company plans to continue its commitment to health promotion with new projects aimed at resource integration and innovative healthcare models in 2026 [4]

Core Viewpoint - The article emphasizes that non-obese individuals are also at risk for fatty liver disease, which can lead to more severe liver damage compared to obese patients [3][4]. Group 1: Research Findings - A study involving nearly 190,000 metabolic-related fatty liver patients found that normal-weight individuals with fatty liver have a 1.14 times higher risk of liver-related events and a 1.31 times higher risk of death from liver disease compared to obese patients [4]. - The study defined normal weight as a BMI of less than 23 kg/m² for the Chinese population and less than 25 kg/m² for the UK population, with approximately 2.7% of fatty liver patients being of normal weight [4]. Group 2: Risk Factors for Normal-Weight Fatty Liver - Factors contributing to fatty liver in normal-weight individuals include poor lifestyle choices, excessive intake of fats and sugars, sedentary behavior, and chronic stress [5]. - Genetic predisposition and age-related mitochondrial dysfunction can also lead to insulin resistance, a key factor in the development of fatty liver [5]. Group 3: Management and Prevention - Recommendations for managing fatty liver in normal-weight individuals include lifestyle interventions aimed at achieving a weight loss of 3% to 5% [6]. - A balanced diet rich in quality proteins, vitamins, and regular aerobic exercise is advised to help reduce the risk of fatty liver [6][8]. - Regular health check-ups are essential for early detection of fatty liver, as it often presents no symptoms in the early stages [8].

Core Insights - The article highlights the increasing prevalence of fatty liver disease in China, with 1 in 3 adults affected, and a concerning trend of younger patients [1] - Fatty liver is often asymptomatic in its early stages, yet it is linked to serious health issues such as hypertension, diabetes, and various cancers [1] - The transition from moderate to severe fatty liver can lead to liver cirrhosis and significantly higher cancer rates compared to healthy individuals [1] Group 1: Health Risks and Statistics - 90% of fatty liver patients show no early symptoms, making it a silent health risk [1] - Moderate fatty liver can progress to cirrhosis in five years, while severe cases have a higher likelihood of developing into liver cancer [1] - Over half of working professionals tend to neglect their health until symptoms become severe, indicating a need for better awareness and proactive health management [1] Group 2: Treatment and Solutions - Traditional views on managing fatty liver emphasize diet and exercise, but recent findings suggest that many cases are not benign and require serious attention [2] - The article introduces Sanqi Fatty Liver Pills, a traditional Chinese medicine approved for treating fatty liver, which aims to address the root causes rather than just the symptoms [2][3] - The product is based on Yunnan's unique natural plant resources and combines traditional medicine with modern pharmaceutical techniques [3] Group 3: Prevention and Management - A comprehensive approach to liver health is recommended, including regular assessments for individuals over 30 and a structured intervention plan involving Sanqi Fatty Liver Pills and physical activity [4] - The article emphasizes the importance of establishing a "prevent-treat-nurture" cycle for liver health, making it as routine as fitness tracking [4] - The narrative stresses that maintaining liver health is crucial for overall well-being, especially for those in demanding work environments [5]